3 Asian Stocks Estimated To Be Trading Below Intrinsic Value In February 2026

As global markets grapple with AI disruption concerns and shifting economic indicators, the Asian stock markets present a unique landscape of opportunities. In this environment, identifying stocks that are trading below their intrinsic value can be particularly appealing to investors seeking potential growth amid broader market volatility.

Click here to see the full list of 223 stocks from our Undervalued Asian Stocks Based On Cash Flows screener.

Let’s dive into some prime choices out of the screener.

Overview: Gentrack Group Limited develops, integrates, and supports enterprise billing and customer management software solutions for the energy, water utility, and airport industries with a market cap of NZ$790.53 million.

Operations: The company’s revenue is derived from two main segments: NZ$36.79 million from the airport industry and NZ$193.40 million from the utility sector.

Estimated Discount To Fair Value: 23.3%

Gentrack Group is trading at NZ$7.43, significantly below its estimated future cash flow value of NZ$9.69, indicating it is undervalued by over 20%. The company has demonstrated strong financial performance with earnings growing by 118.6% in the past year and forecasted to grow at 22.24% annually, outpacing the New Zealand market average of 16.7%. Recent strategic moves include expanding its g2 platform in the UK and Asia-Pacific regions, potentially enhancing future revenue streams.

Overview: Shanghai MicroPort MedBot (Group) Co., Ltd. operates in the medical robotics sector, focusing on developing and commercializing innovative robotic solutions, with a market cap of HK$29.60 billion.

Operations: The company generates revenue of CN¥333.70 million from the sale of medical devices.

Estimated Discount To Fair Value: 23%

Shanghai MicroPort MedBot is trading at HK$28.7, over 20% below its estimated future cash flow value of HK$37.25, suggesting it is undervalued. The company forecasts substantial revenue growth of 110% to 120% for 2025, driven by its Toumai laparoscopic surgical robot’s commercial success and the recent approval of the UniPath bronchoscopic system in China. This positions MicroPort MedBot as a growing force in the surgical robotics industry despite recent share price volatility.

Overview: Qyuns Therapeutics Co., Ltd. is a clinical-stage biotech company focused on developing biologic therapies for autoimmune and allergic diseases in China, with a market cap of HK$4.61 billion.

Operations: The company generates revenue of CN¥320.36 million from its biologic therapies targeting autoimmune and allergic diseases in China.

Estimated Discount To Fair Value: 44.6%

Qyuns Therapeutics, trading at HK$20.52, is significantly undervalued compared to its estimated future cash flow value of HK$37.05. The company is expected to become profitable within three years, with earnings projected to grow 47.08% annually. Recent developments include a licensing agreement for WIN027 worth up to $700 million and progress in clinical trials for QX030N/CLD-423, enhancing its pipeline’s potential in the immunology sector and supporting long-term growth prospects.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NZSE:GTK SEHK:2252 and SEHK:2509.

This article was originally published by Simply Wall St.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com